An observational study in Breast Cancer, sponsored by West Pomeranian Cancer Center. Completed at 3 sites in Poland. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-12-08.
Sponsored by West Pomeranian Cancer Center · Observational
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with anthracyclines based chemotherapy.
Blood will be taken
Echocardiography will be performed
Training set will consist of sera of 30 patients who has reached an end point. Training set will be sequenced using next generation sequencing.
Training set will be used to derive a miRNA signature capable of separating early cardiotoxicity patients from healthy ones. MiRNA signature will be validated using validation set.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 128 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →This is the only study on the registry with West Pomeranian Cancer Center as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Women with newly diagnosed breast cancer that will be treated with anthracyclines will be recruited.
Exclusion Criteria:
Cardiotoxicity events according to CREC (Cardiac Review and evaluation Committee) criteria
either a cardiomyopathy with decreased left ventricular ejection fraction (LVEF), a reduction of LVEF ≥5% to \<55% with symptoms of heart failure (e.g. orthopnoea and paroxysmal nocturnal dyspnoea, elevated jugular venous pressure, S3 gallop, Hepatojugular reflux, tachycardia), or an asymptomatic reduction of LVEF ≥10% to \<55%
Time frame: up to 76 weeks after chemotherapy conclusion
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.